OraSure Technologies, Inc. $OSUR Stock: Private Management Group Inc. Decreases Position

Private Management Group Inc. lessened its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 16.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,180,007 shares of the medical instruments supplier’s stock after selling 617,675 shares during the period. Private Management Group Inc.’s holdings in OraSure Technologies were worth $12,466,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of OSUR. Headlands Technologies LLC bought a new position in OraSure Technologies during the 2nd quarter worth approximately $67,000. Susquehanna International Group LLP increased its stake in OraSure Technologies by 29.4% in the 2nd quarter. Susquehanna International Group LLP now owns 198,779 shares of the medical instruments supplier’s stock worth $887,000 after purchasing an additional 45,169 shares during the period. Two Sigma Securities LLC bought a new stake in OraSure Technologies in the second quarter valued at approximately $55,000. Cannell Capital LLC bought a new stake in OraSure Technologies in the second quarter valued at approximately $6,366,289. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of OraSure Technologies during the second quarter valued at approximately $416,000. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

OraSure Technologies Price Performance

NASDAQ OSUR opened at $3.53 on Tuesday. OraSure Technologies, Inc. has a 1 year low of $2.08 and a 1 year high of $4.58. The business’s 50-day moving average is $3.73 and its 200 day moving average is $3.54.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Monday, November 9th. The medical instruments supplier reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.05. The business had revenue of $30.91 million during the quarter, compared to analyst estimates of $31.00 million. OraSure Technologies had a negative return on equity of 19.09% and a negative net margin of 43.70%. As a group, research analysts predict that OraSure Technologies, Inc. will post -0.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on OSUR shares. Craig Hallum upgraded shares of OraSure Technologies to a “strong-buy” rating in a report on Friday, October 23rd. Wall Street Zen raised shares of OraSure Technologies from a “sell” rating to a “hold” rating in a research note on Monday, August 10th. Zacks Research upgraded shares of OraSure Technologies to a “hold” rating in a report on Friday, October 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of OraSure Technologies in a research report on Tuesday, September 1st. One analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, OraSure Technologies presently has an average rating of “Hold” and an average target price of $3.00.

About OraSure Technologies

OraSure Technologies, Inc develops, manufactures and markets diagnostic products and specimen-collection technologies used by healthcare providers, laboratories, researchers and consumers. The company focuses on making testing more accessible through products that support decentralized, point-of-care and at-home testing, as well as laboratory-based molecular and diagnostic workflows.

Its portfolio has included the OraQuick line of rapid diagnostic tests, including oral-fluid tests for HIV and hepatitis C, along with other infectious-disease testing products.